Advocacy intelligence hub — real-time data for patient organizations
Inozyme Pharma — PHASE3
Inozyme Pharma
Inozyme Pharma — PHASE3
Inozyme Pharma — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Autosomal recessive hypophosphatemic rickets news →
Kurt Gunter, MD, M.D
Inozyme Pharma, Inc.
📍 BEVERLY, MA
Pedro Huertas, MD, M.D
Inozyme Pharma
📍 CONCORD, MA
Carlos R Ferreira Lopez, M.D.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
📍 Bethesda, Maryland
Alex Lai, MD
Inozyme Pharma
View all Autosomal recessive hypophosphatemic rickets specialists →